Original articleEffects of statin therapy on weight loss and diabetes in bariatric patients
Section snippets
Participants
We reviewed data from our prospectively maintained database of patients who underwent bariatric surgery at our center. A total of 2878 patients underwent bariatric surgery with 1 of 2 surgeons. Procedures included laparoscopic adjustable gastric banding (LAGB; n = 1776), RYGB (n = 939), and sleeve gastrectomy (SG; n = 163). We included only patients who had statin use and diabetes status data before surgery and completed 1-year follow-up visits for a final sample size of 1575 patients (1035
Baseline characteristics
Patients using statins preoperatively were more likely to have diagnosed hypertension and hyperlipidemia; higher triglycerides, fasting glucose, insulin and HbA1C values; and lower total and LDL cholesterol (Table 1). Women comprised 481 statin users (71.7%) versus 750 nonstatin users (83.0%; χ2 = 28.7; P<.01). In addition, more patients (χ2 = 162.8; P<.01) on statins had type 2 diabetes (T2D) (Fig. 1). There were no differences in statin use among surgery types (χ2 = .17; P = .92) with 597
Discussion
This study is, to our knowledge, the first to examine the influence of statin therapy on diabetes status, weight loss, and metabolic changes after bariatric surgery. Our results suggest that preoperative statin therapy, as well as statin use in the ensuing postsurgical year, does not have a detrimental impact on bariatric weight loss, metabolic outcomes and diabetes risk. We did, however, observe that patients who ceased statin therapy from preoperative use to 1-year follow-up were more likely
Conclusion
Our results indicate that there is no detrimental effect of preoperative statin therapy on weight loss or change in BMI in bariatric surgical patients, and statin use was associated with increased weight loss in RYGB patients. In addition, preoperative statin use did not increase the number of new onset diabetes cases, and improved the likelihood of diabetes remission relative to patients not using preoperative statins. However, ceasing statin therapy after surgery was associated with greater
Disclosures
The authors have no commercial associations that might be a conflict of interest in relation to this article.
References (21)
- et al.
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Lancet
(2015) - et al.
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Lancet
(2012) - et al.
Simvastatin impairs exercise training adaptations
J Am Coll Cardiol
(2013) - et al.
Statin therapy with or without ezetimibe and the progression to diabetes
J Clin Lipidol
(2016) - et al.
National prevalence, causes, and risk factors for bariatric surgery readmissions
Am J Surg
(2016) - et al.
Changes in the makeup of bariatric surgery: a national increase in use of laparoscopic sleeve gastrectomy
J Am Coll Surg
(2013) - et al.
Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins?
JAMA Intern Med
(2014) - et al.
Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress
J Appl Physiol (1985)
(2011) - et al.
Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications
Muscle Nerve
(2011) Do statins increase the risk of diabetes or is it guilt by association?
Curr Opin Endocrinol Diabetes Obes
(2014)